Nichakawade, Tushar D. http://orcid.org/0000-0002-4091-7580
Ge, Jiaxin http://orcid.org/0000-0001-9152-6267
Mog, Brian J. http://orcid.org/0000-0001-9988-7147
Lee, Bum Seok
Pearlman, Alexander H. http://orcid.org/0000-0002-3504-7517
Hwang, Michael S.
DiNapoli, Sarah R.
Wyhs, Nicolas
Marcou, Nikita http://orcid.org/0000-0003-0232-081X
Glavaris, Stephanie
Konig, Maximilian F. http://orcid.org/0000-0001-5045-5255
Gabelli, Sandra B. http://orcid.org/0000-0003-1205-5204
Watson, Evangeline
Sterling, Cole
Wagner-Johnston, Nina
Rozati, Sima
Swinnen, Lode
Fuchs, Ephraim
Pardoll, Drew M. http://orcid.org/0000-0001-6215-1013
Gabrielson, Kathy
Papadopoulos, Nickolas http://orcid.org/0000-0001-7135-7451
Bettegowda, Chetan http://orcid.org/0000-0001-9991-7123
Kinzler, Kenneth W.
Zhou, Shibin http://orcid.org/0000-0003-1941-4425
Sur, Surojit
Vogelstein, Bert http://orcid.org/0000-0003-0766-3854
Paul, Suman http://orcid.org/0000-0001-9357-3702
Article History
Received: 19 April 2023
Accepted: 16 February 2024
First Online: 27 March 2024
Competing interests
: The Johns Hopkins University has filed patent applications related to technologies described in this paper on which S.P., T.D.N., B.V., K.W.K., N.P. and S.Z. are listed as inventors. S.P. is a consultant to Merck, owns equity in Gilead and received payment from IQVIA and Curio Science. B.V., K.W.K. and N.P. are founders of Thrive Earlier Detection, an Exact Sciences Company. K.W.K. and N.P. are consultants to Thrive Earlier Detection. B.V., K.W.K., N.P. and S.Z. hold equity in Exact Sciences. B.V., K.W.K., N.P. and S.Z. are founders of or consultants to and own equity in ManaT Bio, Neophore and Personal Genome Diagnostics. B.V., K.W.K. and N.P. hold equity in Haystack Oncology and CAGE Pharma. N.P. is a consultant to Vidium. M.F.K. received personal fees from Argenx, Atara Biotherapeutics, Revel Pharmaceuticals, Sana Biotechnology, Sanofi and Doximity, all unrelated to this work. B.V. is a consultant to and holds equity in Catalio Capital Management. S.Z. has a research agreement with BioMed Valley Discoveries. C.B. is a consultant to Depuy-Synthes, Bionaut Labs, Haystack Oncology, Privo Technologies and Galectin Therapeutics; a co-founder of OrisDx; and a co-founder of Belay Diagnostics. D.M.P. reports grant and patent royalties through institution from BMS, a grant from Compugen, stock from Trieza Therapeutics and Dracen Pharmaceuticals and founder equity from Potenza; being a consultant for Aduro Biotech, Amgen, Astra Zeneca (Medimmune/Amplimmune), Bayer, DNAtrix, Dynavax Technologies Corporation, Ervaxx, FLX Bio, Rock Springs Capital, Janssen, Merck, Tizona and Immunomic Therapeutics; being on the scientific advisory board of Five Prime Therapeutics, Camden Nexus II, WindMil; and being on the board of directors for Dracen Pharmaceuticals. The companies named above, as well as other companies, have licensed previously described technologies related to the work described in this paper from Johns Hopkins University. B.V., K.W.K. and N.P. are listed as inventors of some of these technologies. Licences to these technologies are or will be associated with equity or royalty payments to the inventors as well as to Johns Hopkins University. Patent applications on the work described in this paper may be filed by Johns Hopkins University. The terms of all of these arrangements are being managed by Johns Hopkins University according to its conflict of interest policies.